Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arbutus Biopharma Corporation stock | $3

Own Arbutus Biopharma Corporation stock in just a few minutes.

Fact checked

Arbutus Biopharma Corporation is a biotechnology business based in the US. Arbutus Biopharma Corporation shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma Corporation employs 78 staff and has a trailing 12-month revenue of around USD$6.1 million.

How to buy shares in Arbutus Biopharma Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Arbutus Biopharma Corporation. Find the stock by name or ticker symbol: ABUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arbutus Biopharma Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arbutus Biopharma Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Arbutus Biopharma Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Arbutus Biopharma Corporation share price

Use our graph to track the performance of ABUS stocks over time.

Arbutus Biopharma Corporation shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$3
52-week rangeUSD$0.88 - USD$6.48
50-day moving average USD$3.8635
200-day moving average USD$3.107
Wall St. target priceUSD$7
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.79

Buy Arbutus Biopharma Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arbutus Biopharma Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arbutus Biopharma Corporation price performance over time

Historical closes compared with the close of $3 from 2020-10-19

1 week (2021-01-13) -25.74%
1 month (2020-12-18) -31.03%
3 months (2020-10-20) 4.17%
6 months (2020-07-20) 1.01%
1 year (2020-01-17) -2.28%
2 years (2019-01-18) -18.70%
3 years (2018-01-19) 5.2
5 years (2016-01-20) 3.51

Arbutus Biopharma Corporation financials

Revenue TTM USD$6.1 million
Gross profit TTM USD$-51,590,000
Return on assets TTM -25.05%
Return on equity TTM -78.86%
Profit margin 0%
Book value $1.225
Market capitalisation USD$328.6 million

TTM: trailing 12 months

Shorting Arbutus Biopharma Corporation shares

There are currently 2.9 million Arbutus Biopharma Corporation shares held short by investors – that's known as Arbutus Biopharma Corporation's "short interest". This figure is 37.8% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Arbutus Biopharma Corporation shares can be evaluated.

Arbutus Biopharma Corporation's "short interest ratio" (SIR)

Arbutus Biopharma Corporation's "short interest ratio" (SIR) is the quantity of Arbutus Biopharma Corporation shares currently shorted divided by the average quantity of Arbutus Biopharma Corporation shares traded daily (recently around 4.9 million). Arbutus Biopharma Corporation's SIR currently stands at 0.6. In other words for every 100,000 Arbutus Biopharma Corporation shares traded daily on the market, roughly 600 shares are currently held short.

However Arbutus Biopharma Corporation's short interest can also be evaluated against the total number of Arbutus Biopharma Corporation shares, or, against the total number of tradable Arbutus Biopharma Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arbutus Biopharma Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Arbutus Biopharma Corporation shares in existence, roughly 30 shares are currently held short) or 0.0438% of the tradable shares (for every 100,000 tradable Arbutus Biopharma Corporation shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arbutus Biopharma Corporation.

Find out more about how you can short Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation share dividends

We're not expecting Arbutus Biopharma Corporation to pay a dividend over the next 12 months.

Have Arbutus Biopharma Corporation's shares ever split?

Arbutus Biopharma Corporation's shares were split on a 1:5 basis on 4 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma Corporation shares which in turn could have impacted Arbutus Biopharma Corporation's share price.

Arbutus Biopharma Corporation share price volatility

Over the last 12 months, Arbutus Biopharma Corporation's shares have ranged in value from as little as $0.88 up to $6.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 3.2724. This would suggest that Arbutus Biopharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arbutus Biopharma Corporation overview

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site